Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Favipiravir in Patients with Early-Onset COVID-19 with Risk Factors for Progression to Severe Symptoms

Next Previous
Trial Profile

A Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Favipiravir in Patients with Early-Onset COVID-19 with Risk Factors for Progression to Severe Symptoms

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Favipiravir (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors FUJIFILM Toyama Chemical

    • Most Recent Events

    • 11 Mar 2022 According to a FUJIFILM Toyama Chemical media release, majority of enrolled patients infected by the Omicron strain, even if trial were continued under the current clinical trial protocol, it would be difficult to verify efficacy of Avigan to suppress the symptoms from becoming severe, hence company decided to terminate the enrollment of new subjects into this trial and clinical data of the patients enrolled in the trial will be analyzed.
    • 23 Apr 2021 New trial record
    • 21 Apr 2021 According to a FUJIFILM Toyama Chemical media release, this trial design was based on the findings from the phase III clinical trial implemented last year, that Avigan expedited the improvement of symptoms in early-onset patients.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top